Introduction
The systemic vasculitides represent a significant anagement problem to many different specialties. Their impact on health care resources is out of proportion to their incidence, because patients ?re usually severely ill and often require intensive Inpatient care and follow up. : Although often described as 'rare', recent stud-!es suggest the incidence of vasculitis may be lllcreasing. 1 In Norfolk we have registered all new patients with vasculitis for the last two years; ea.rly analysis suggests Wegener's granulomatosis, microscopic polyarteritis and systemic rheumatoid vasculitis each have a similar incidence of between seven and ten per million per year, systemic vasculitis in general occurring in at least 25 per illion per year. This compares with previous figures suggesting an incidence for systemic vasculitis of between five and ten per million per year. This apparent increase in part reflects an increased understanding and recognition of the yarious diseases. A review of their management IS, therefore, timely and appropriate, not only to Specialists with specific interests in vasculitis but also to all clinicians working within the sphere of acute general medicine and surgery.
Definition
The vasculitides are a heterogeneous group of uncommon diseases characterized by inflammatory cell infiltration and necrosis of blood vessel walls.s This can occur as a primary event (e.g. polyarteritis nodosa, Wegener's granulomatosis, etc.) or secondary to other established diseases such as rheumatoid arthritis and systemic lupus erythematosus.
The clinical and pathological consequences of such vascular inflammation depend on the site, size and number of blood vessels, affected. Vasculitis may be localized and clinically insignificant or more generalized with severe life-threatening complications. Muscular arteries can develop focal lesions (involving part of the vessel wall) with aneurysm formation and potential rupture or segmental lesions (affecting the whole circumference) with associated stenosis, occlusion and peripheral gangrene. Small vessel vasculitis most commonly affects the skin and is rarely associated with serious internal organ dysfunction, but widespread small vessel vasculitis can cause problems.
Because of the varied prognosis associated with different vasculitides, many attempts have been made to define accurately each disease entity so that comparisons can be made between various therapeutic regimens in different geographical centres. Thus, the American College of Rheumatology recently published criteria for the 'classification of vasculitis'.:' This multicentred study compared patients with seven different vasculitic diseases producing various classification criteria for polyarteritis nodosa, Wegener's granulomatosis, Churg-Strauss vasculitis, hypersensitivity vasculitis, Henoch-Schonlein purpura, giant cell arteritis and Takayasu's arteritis (see Tables 2, 4, 5) . Each disease group was compared to the other six, the whole series representing 807 patients collected from 47 different medical centres in the USA, Canada and Mexico. These and similar approaches from other centres should help evaluate the different groups of vasculitic patients in therapeutic and epidemiological studies. They do not, unfortunately, contribute toward any overall classification system (see below).
Classification
The classification we favour is based on the size of the predominent vessel involved and the type of inflammatory change (Table 1 ). This classification is based on the earlier work of Zeek-and Alarcon-Segovia and Brown,s but excludes groups of infectious vasculitis and 'vasculitis look-alikes'. This latter group were included in a similar classification system (to ours) favoured by Lie." The importance of this classification is that patients in group 1 tend to have more severe systemic disease with the poorest prognosis which appears to benefit most from aggressive immunosuppressive Table1 Classification of vasculitis treatment. Group 2 has a more varied clinical pattern of disease, especially involving the skin and rarely threatens life. This review willtherefore concentrate particularly on the diseases in group 1 (polyarteritis nodosa, Wegener's granulomatosis, systemic rheumatoid vasculitis, etc.) and group 3.
This classification does not specifically include the newer diagnostic' immunological tests. However, the patients whose disease is associated with anti neutrophil cytoplasmic antibodies (ANCA) and also those with the highest levels of von Willebrand's factor antigen are almost all found in Group 1. ANCA and von Willebrand's factor antigen measurements have an important role in diagnosis and treatment so will be discussed in more detail later.
Investigations
Nonspecific abnormalities are commonly detected in routine laboratory tests, including anaemia and leucocytosis. Almost all patients with primary vasculitis have significantly raised white counts though we have seen two patients presenting with leucopenia. Patients with secondary vasculitis complicating rheumatoid arthritis and systemic lupus erythematosus often have normal white counts, despite active disease. There is also evidence of an acute phase response (raised ESR (erythrocyte sedimentation rate), C-reactive protein (CRP), etc.). In long-term studies, the CRP has been shown to be the best non-specific assessment of disease activity. E?sinophilia is seen most frequently in patients with allergic (Churg-Strauss) vasculitis, but mild eosinophilia can occur in rheumatoid vasculitis nd .other systemic vasculitides. Mild increases I~liver enzymes are common, also reflecting dIsease activity, though very high levels raise the possibility of hepatitis B infection. Investigations to exclude infection are commonly undertakeñ ecause of the non-specific presentation which mcludes fever in many patients. Some cases of vasculitis follow infections with streptococci, epatitis B, toxoplasma and cytomegalovirus, but In the majority of cases there is no evidence of any associated infectious illness.
Laboratory tests are also undertaken to detect specific organ involvement which varies between the different diseases (chest X-ray, sinus X-ray, etc.) More specific tests try to define the type and extent of vascular involvement such as tissue biopsy (renal, lung, nasal, muscle, etc.) and angiography. Biopsies should always be taken from 'involved' organs as blind biopsies are rarely helpful. For example, biopsy of painful muscles gives a positive result in over 60% but of non-tender muscles in only 30%. In contrast, renal, skin or open lung biopsy gives a positive diagnosis in almost 100% of cases (Table 2) . 7 Angiography should include the coeliac axis and bilateral renal angiograms with a pick-up rate of up to 70% in polyarteritis nodosa.f Aneurysms are also detected in other diseases in group 1 but much less commonly." In Wegener's granulomatosis white cell scans may be helpful in demonstrating disease activity (increased uptake) and also 
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identify sites for further investigation including tomography and possible biopsy.
Renal involvement is the most important prognositc indicator in polyarteritis nodosa and Wegener's granulomatosis where a serum creatinine of more than 500 p,mol/I is associated with a significant increase in mortality (see later). It is vital, therefore, to detect renal involvement early; the single most important investigation is a simple labstix testing of urine which should be performed daily in all cases of suspected vasculitis. The presence of haematuria and/or proteinuria in the absence of infection is an indication for urgent investigation because renal failure can develop within days in some patients. In one series the diagnosis of vasculitis was delayed for up to six weeks from first presentation to hospital and during this period many patients had significant deterioration of renal function, some becoming dialysis-dependent and others dying of renal failure. Other patients treated early with relatively mild renal involvement usually had complete recovery of renal function.!" A variety of immunological abnormalities have also been described. Auto-antibodies usually reflect the underlying disease in secondary vasculitis -rheumatoid factor in rheumatoid arthritis, DNA binding in systemic lupus erythematosus, etc. In rheumatoid disease, rheumatoid factor levels often increase in the presence of vasculitis which is also associated with evidence of rheumatoid factor containing complement fixing circulating immune complexes.U In polyarteritis nodosa and Wegener's granulomatosis, circulating immune complexes are also commonly detected but complement levels are usually normal or raised, except in patients whose disease is associated with hepatitis B infection.ts These studies suggest that immunological factors are of little importance in polyarteritis and Wegener's granulomatosis and this is supported by the finding of little or no immunoglobulin deposition in affected tissues including the kidney. However, the description of ANCA in Wegener's granulomatosis and polyarteritis nodosa has placed these diseases firmly back in the 'autoimmune category'. ANCA are now measured routinely in investigation of all patients with suspected vasculitis and their relevance and specificity to the different vasculitides needs to be discussed in detail.
Antineutrophil cytoplasmic antibodies (ANCA)
Davies et a/. 13 first described the presence of ANCA in a group of patients with segmental glomerulonephritis. Subsequently further reports l4-16 demonstrated the high sensitivity of ANCA in Wegener's granulomatosis and its Correlation with disease activity. The indirect immunofluorescence test is the most widely accepted method for detecting ANCA,17 identifying at least two different patterns of staining: cytoplasmic or C-ANCA (directed against proteinase 3) which produces a coarsely granular, centrally accentuated immunofluorescence; and perinuclear ANCA, or P-ANCA, which gives a perinuclear staining pattern and which reacts mainly with myeloperoxidase, but also with elastase. 18 Enzyme-linked immunosorbent assays (ELISA) using purified primary granules from neutrophils or myeloperoxidase have also been developed which permit more objective determination of ANCA; these techniques are particularly useful in patients who also have antinuclear antibodies which may obscure the cytoplasmic staining. 19 Most reviews suggest a specificity of C-ANCA in Wegener's granulomatosis of over 90%, but C-ANCA is also seen in some patients with microscopic polyarteritis.P idiopathic crescentic glomerulonephritis, adult Henoch-Schonlein purpura, Churg-Strauss vasculitis, Kawasaki disease 20 and systemic rheumatoid vasculitis -diseases classified in group 1. It is partly because of the association of ANCA with idiopathic crescentic glomerulonephritis that this disease is now thought of as part of the systemic vasculitis spectrum.
We have seen a small number of patients with rheumatoid vasculitis and high titres of ANCA. Some had particularly widespread vasculitis mimicking polyarteritislWegener's granulomatosis, but four patients had relatively mild cutaneous vasculitis.s! Preliminary studies suggest that, although all patients had C-ANCA on immunofluorescence, the specificity of the antibodies differed between the two groups (Lockwood, personal communication). Clearly, further developments along these lines may improve our understanding of the role of the antibodies in different vasculitic diseases and their value in diagnosis and management.
ANCA have also rarely been associated with other diseases, including systemic lupus erythematosus, relapsing polychondritis, Behcet's disease and Takayasu's arteritis.P Again these are all systemic vasculitides but the association here appears weaker. Finally, there has been a description of ANCA in patients with cystic fibrosis which is not specifically associated with any vasculitis.P This may reflect the dominant pulmonary involvement of this condition with neutrophil infiltration similar to that seen in pulmonary Wegener's. 'ANCA-associated vasculitis' is a term used by some authors to describe a group of patients with vasculitis who may be difficult to classify by conventional means.
The most problematic nomenclature issue in patients with ANCA-associated diseases is what term should be used for non-granulomatous pulmonary-renal syndromes. Because there is no granulomatous inflammation, they do not meet the classic criteria for Wegener's granulomatosis. An international committee is currently considering a nomenclature system for ANCAassociated diseases that would include a generic category for ANCA-associated pulmonary syndromes (called Wegener's syndrome) that would include Wegener's granulomatosis and nongranulomatous pulmonary-renal syndromes (called Wegener's vasculitisj.>' These patients still have severe multiorgan disease and require aggressive immunosuppressive treatment similar to more typical cases of polyarterits and Wegener's granulomatosis.
ANCA have now established the systemic vasculitides as part of the autoimmune disease spectrum. They are routinely used in the analysis of any patients with suspected vasculitis and have proved useful in monitoring disease activity where the presence of persistently high levels of antibody are associated with a high risk of relapse in Wegener's granulomatosis. This is a rapidly developing field and it is possible that future classification systems will be based on the results of specific auto-antibody analysis as well as clinical and pathological assessments of the various vasculitic diseases. In some circumstances, (e.g. classical clinical presentation but patient on anticoagulants) high titres of ANCA may make tissue biopsy unnecessary. However, because of the increasing numbers of diseases associated with this antibody, we still favour its use as an adjunct to diagnosis in most cases.
Von Willebrand's factor antigen
Von Willebrand's factor antigen is an endothelial cell based protein and raised plasma levels give indirect evidence of vascular endothelial damage. High levels of the antigen have been described, particularly in patients with systemic necrotizing arteritis.P This test is not specific, however, as raised levels are also seen in patients with both venous and arterial thrombosis and after surgery. However, in patients with suspected systemic vasculitis particularly high levels are more suggestive of the type of patients seen in group 1 nd again would suggest the use of more aggressive Immunosuppressive therapy.
Clinical features and treatment of specific diseases
An accurate assessment of the success of different therapeutic regimens used to treat systemic vasculitis is difficult because of the previous lack of specific classification criteria for the different diseases. Different authors describe different treatments in slightly different groups of patients, making direct comparisons impossible. This did not really matter 20 years ago when the majority of patients died from uncontrolled vasculitis, but now that successful treatment is available it is important to compare different regimens in different centres in the same groups of patients using the recently described American College of Rheumatology classification criteria. . Before the development of steroids and Immunosuppressive drugs the mortality of most systemic vasculitides are high: 80% one-year mor-t~lity in Wegener's granulomatosis 26 and 85% five-year mortality in polyarteritis nodosa. 27 ,28 The prognosis of systemic vasculitis has improved dramatically over the last 20 years, especially with the use of potent immunosuppressive drugs. This Was most dramatically demonstrated in Wegener's granulomatosis by Fauci and his colleagues who have shown an improved five year survival to over 85%. Different diseases respond differently to immunosuppressive drugs and it is appropriate, therefore, to review briefly the major clinical features of the commoner vasculitic diseases and different approaches to their management.
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Wegener's granulomatosis Wegener's granulomatosis is a distinct clinicopathological entity characterized by necrotizing granulomatous lesions of the upper and lower respiratory tract, focal segemental necrotizing glomerulonephritis and variable degrees of small vessel vasculitis 29 ,30 (Figure 1 ). The American College of Rheumatology classification criteria for Wegener's granulomatosis are shown in Table  3 .
Presenting features
Early symptoms may be non-specific with fever, malaise, weight loss, arthralgias and myalgias. Sinus pain, purulent nasal discharge, epistaxis, nasal mucosal ulceration and otitis media are also common, suggesting upper airways involvement.
Involvement of the upper or lower respiratory tract is still the major case for seeking medical attention in most patients (90%). Many patients, in the early stages, may be misdiagnosed as having an infection or allergy, particularly in the absence of systemic illness, but persistent upper or lower respiratory symptoms in the presence of haematuria and/or proteinuria, aided by a positive ANCA test, should prompt the physician to perform a definite biopsy of the clinically involved organ, In 30% of cases the absence of rigorous pursuit for diagnosis, the lack of symptomatic pulmonary and renal findings or the indolent cause of the illness led to long delays in diagnosis (longer than one year). Pulmonary involvement in the form of nodules and/or infiltrates occurs in 45% of patients. The symptoms arising from such involvement of the lung include cough (19%), haemoptysis (12%) and pleuritis (10%). In one series, in about 34% of cases, radiographs of the chest showed infiltrates or nodules that were asymptomatic. Eight-five per cent of patients eventually develop lung disease related Wegener's granulomatosis.U Renal involvement in many patients can also be asymptomatic (18%). However, severe glomerulonephritis usually develops within two years of disease onset. The presence of haematuria and/or proteinuria on routine analysis is the most frequent method of detecting renal involvement. Such a finding needs urgent investigation, including biochemical examination of renal function and renal biopsy (see below).
Ocular involvement may be one of the early features of the disease, occurring in approximately 15% of patients. Many will have non-specific symptoms, but the presence of proptosis, particularly when it occurs in the setting of upper and lower airway disease or renal involvement, suggests Wegener's granulomatosis. Proptosis as a presenting feature of Wegener's granulomatosis occurs in 2% and may be present in about 15% at some time during the illness.U It is a serious complication leading to loss of vision from optic nerve ischaemia. Occasionally entrapment of an extraocular muscle may lead to gaze palsy.
Other manifestations
Arthralgia and frank arthritis is not common, occurring in approximately 67% of patients at some stage of the disease. Rarely symmetrical involvement of large and small joints, in conjunction with a false positive test for rheumatoid factor (60%), may lead to an incorrect diagnosis of rheumatoid arthritis. It is not uncommon to see monoarthritis, pauci-articular or migratory arthritis. Predominant joint manifestations with-?ut~ny extra-articular features may lead to delay In diagnosis of Wegener's granulomatosis. Fever, as the presenting symptom , may be present in 23% and occurs in 50% during the illness. Significant weight loss (greater than 10% of usual weight) can occur in 15% of patients at the disease onset and 35% overall. Skin disease, in the form of the palpable purpura, ulcers, vesicles, papules and subcutaneous nodules, can occur in 13% of patients at presentation and 46% of patients t some stage of their illness. Nervous system Involvement is rare in Wegener's granulomatosis 8%) although mononeuritis multiplex develops In a significant proportion of patients (15%). Cardiovascular involvement occurs much less frequently (2%). Very rarely, « 1%) Wegener's granulomatosis can involve the parotid, breast, cervix, vagina or urethra.
Pathology
. Wegener's granulomatosis is, pathologically, characterized by the triad of (1) aseptic granulo-. matous necrosis of the upper or lower respiratory tract or both, (2) small vessel vasculitis usually selectively in systemic organs, such as lung and kidney, and (3) focal segmental glomerulitis. The vasculitis may be granulomatous or nongranulomatous and tends to be focal in distributioñ ith some abdundance of eosinophils within the Inflammatory infiltrate.
One study reports on the varieties of parenchymal and vascular changes seen in patients with Wegener's granulomatosis.V Combined vasculitis and necrosis were found in 89% of biopsy samples in this series; granulomas and necrosis were found in 90%; the combination of granulomas and vasculitis as well as vasculitis, necrosis and granulomatous inflammation were found in 91% of biopsy specimens. . The characteristic finding from renal biopsy In patients with Wegener's granulomatosis is segmental necrotizing glomerulonephritis which tends to be focal. In one series-! 144 renal biopsies from 103 patients showed segmental necrotizing glomerulonephritis in 80%. Vasculitis unrealted to glomerular vessels occurred in 8% and vasculitis and granulomatous changes were both present in Clinical aspects a/systemic vasculitis ill adults 201 3% of specimens.
Skin lesions commonly show Ieucocytoclastic vasculitis and, less commonly, dermal necrotizing granulomas or necrotizing vasculitis involving dermal arteries and veins.
Overall 79% of patients have biopsy evidence of vasculitis and 89% evidence of both vasculitis and granulomatosis.
Treatment
Early treatment is still important because of the potential for tissue destruction involving bone and cartilage within the upper airways in this phase of the disease (Figure 2) . After a variable time, the disease becomes more widespread and systemic with skin, eye, nerve and renal involvement (similar to polyarteritis nodosa). The development of renal disease is the most important prognostic factor as without treatment the mean survival is only five months and the prognosis, even with appropriate treatment, is significantly worse than in patients without impaired renal function. Careful monitoring of renal function in all patients with Wegener's granulomatosis is essential.
Corticosteroids were used in the 1950s to treat Wegener's granulomatosis and produced apparent early remissions, but this improvement was short-lived and associated in many cases with sepsis and without any improvement in long-term outcome. Cytotoxic drugs (especially cyclophosphamide) were first used in the late 1960s with dramatic effect. Long-term survival improved from five months (no treatment) to 12 months (steroids), to 80% five-year survival with cyclophosphamide.Po'" These figures have been verified in different centres but the largest experience of cyclophosphamide treatment for Wegener's granulomatosis is from the National Institutes of Health (NIH). Fauci et at. recently reported their experience on 133 patients where a partial remission was claimed to have been obtained in 91% of patients with daily cyclophosphamide and corticosteroid and a complete remission in 75%. 31 In patients on remission conversion of daily corticosteroid treatment to alternate day doses occurred after a median period of 3.2 months with complete discontinuation of steroid treatment by 12 months. However, 50% of complete remissions were followed by one or more relapses occurring between three months and 16 years. Our own experience in smaller numbers suggests that over 50% of patients have persistent disease suppressed by cyclophosphamide but not necessarily cured.
The most effective treatment schedule for using cyclophosphamide has not yet been established. The NIH studies have all used continuous oral cyclophosphamide, but because of potential side effects we and others have developed intermittent pulsed intravenous and oral regimens. Patients with severe renal involvement have a higher mortality (37.5%) even with cyclophosphamide treatment. Long-term follow up (eight years) of these patients also reveals a tendency to relapse and stresses the need for long-term immunosuppression.P In some patients, Wegener's granulomatosis appears to be restricted to the upper and/or lower respiratory tracts ('limited Wegener's').
These patients may have systemic symptoms (fever, malaise, etc.) and also skin and eye involvement. Laboratory abnormalities are milder and only 50% are ANCA positive. One series of limited Wegener's granulomatosis patients who underwent renal biopsy, despite an absence of clinically apparent renal involvement showed histological changes in five out of 16 cases. Long-term follow up suggests some but not all patients go on to develop significant renal disease, again highlighting the need for careful monitoring of this disease. Occasionally patients are seen with 'renal limited disease' who develop a reverse sequence of organ involvernent.w-V One study (Table 4 ) compared nine 'limited Wegener's' patients with 16 patients with 'classical Wegener's' and showed less constitutional upset and fewer abnormalities of such laboratory tests as haemoglobin, white cell and platelet count in the limited Wegener's group. There was no mortality in limited Wegener's patients but locally destructive disease (e.g. subglottic stenosis leading to tracheostomy and ocular damage leading to enucleation of the eye, etc.) stress the potentially severe morbidity of limited Wegener's and the need still to use aggressive immunosuppressive treatment.w
Other treatments have also been used to treat Wegener's granulomatosis with success, notably co-trimoxazole. The numbers studied are still small but dramatic responses have been described, especially in the limited form of the disease-? (Table 5 ).
Polyarteritis nodosa
Kussmaul and Maiers? first described a multisystem disease involving the skin, gut, joints, peripheral nerves and kidney characterized by inflammation of small and medium sized arteries with palpable nodules along the vessel. This condition arises de novo but similar clinical and pathological changes are seen in association with malignant diseases including hairy cell leukaemia and lymphoma, and also in association with connective tissue diseases such as rheumatoid arthritis," Sjogren's syndrome's and mixed cryoglobulinaemia.P Some patients have predominantly renal involvement characterized by histological appearances of focal segmental necrotizing glomerulonephritis. This probably represents involvement of the afferent glomerular arterioles indicating smaller vessel disease; the term microscopic polyarteritis is sometimes used to describe these c~anges. Patients with predominantly mediumsized artery-involvement are more prone to develop frank haematuria and renal infarction whereas patients with microscopic polyarteritis evelop renal parenchymal damage and sometimes rapidly progressive renal failure. Larger vessel disease (characterized by mononeuritis multiplex and aneurysms on angiography) is known as 'classical polyarteritis nodosa' to contrast with microscopic polyarteritis nodosa ( Table  6 ). These represent two ends of a broad spectrum a~many patients show overlapping features, especially those undergoing multiple tissue biopsy or Who come to necropsy where detailed histological examination can be made. The spectrum is also seen in long-term follow-up studies where microscopic polyarteritis nodosa may relapse with features of classical polyarteritis nodosa.
The incidence and prevalence of polyarteritis nodosa are difficult to estimate because of the difficulty with definition (systemic vasculitis, classical polyarteritis, microscopic polyarteritis, etc.) 10 different series. There is a wide age range (peaks in the fifties and sixties) and a slight male preponderance. The aetiology is unknown except in a minority of cases associated with hepatitis B infec-tion. Of more than 100 patients with polyarteritis nodosa seen in Bristol, Birmingham and Norwich, only four had disease associated with hepatitis B infection. This contrasts with some American and South American centres where a frequency of over 50% has been reported. 44 The American College of Rheumatology has recently published classification criteria for polyarteritis similar to those for Wegener's granulomatosis (Table 7) . 
Clinical features
The disease may present in a variety of ways. There is a spectrum of severity from mild, limited disease to severe and progressive disease. It is not uncommon to see patients with predominant constitutional symptoms such as fever, weight loss, lassitude and tiredness along with manifestations of multisystem involvement such as skin rash, peripheral neuropathy and an asymmetric polyarthritis. Renal or gut involvement may be present at presentation or may occur later.
The presenting features of polyarteritis nodosa are shown in Table 6 .
Pathology
The typical pathological lesion of classical polyarteritis nodosa is a focal segmental necrotizing vasculitis of medium-and small-sized arteries, less commonly arterioles and rarely venules. Occasionally it can involve a vessel at the site of bifurcation. It can involve any vessel, although it is unusual to have pulmonary or splenic vessel involvement.
The inflammation is characterized by fibrinoid necrosis and pleomorphic cellular infiltration, with predominantly polymorphonuclear leucocytes and variable numbers of lymphocytes and eosinophils. The internal elastic lamina is often disrupted and there may be associated thrombosis and aneurysmal dilatation at the site of the lesion. Subsequent fibrosis may lead to vascular occlusion in certain cases. A characteristic feature of polyarteritis nodosa is segmental 'blow-out' type destruction of the vessel wall resulting in the formation of a microaneurysm. A unique feature of polyarteritis nodosa, histologically, is the coexistence of necrotizing vasculitis and a healed lesion or a normal artery in different tissues or in different parts of the same tissue.
Organ involvement in polyarteritis nodosa can occur at variable rate. The kidney is involved in 7D-80% of cases; gastrointestinal tract (50%), gallbladder (10%), peripheral nerve (50%) and cutaneous involvement varies between a few per cent to 50%. Autopsy studies have also described involvement of testes in 86% of patients, although the clinical symptoms are rare. 
Treatment
Corticosteroids not only suppress the active phase of polyarteritis nodosa but also improve long-term survival (in contrast to Wegener's granulomatosis) from 10% (no treatment) to over 50% at two years. Longer-term studies suggest that this improvement is not maintained, with one series demonstrating a 71% survival at one year ?U! longer-term survival of only 30%.45 Survival IS Improved with aggressive immunosuppressive treatment, particularly with cyclophosphamide and azathioprine, with five-year survival figures ranging between 75 and 85%.46 Patients with severe renal involvement have a poorer long-term O~tcome even in response to cyclophosphamide WIth mortality between 30 and 45%.47 Patients who have the poorest outcome are those with ol~er age of presentation (over 50 years) and those .WIth severe renal impairment (serum creatinine <::: .500 JLmol/l, oliguria or crescents on biopsy) pnor to treatment. The cause of death has altered dramatically over the last decade. Before 1980 the majority of deaths
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were due to active vasculitis or complications such as hypertension. With more appropriate therapy and improved initial outcome the commonest cause of death is now sepsis. The frequency of sepsis appears to relate more to the dose of steroid than to the dose of cyclophosphamide. Relapses despite treatment still occur and one series reported relapse rates of 18% in microscopic polyarteritis nodosa, 43% classical polyarteritis nodosa, 40% systemic Wegener's granulomatosis, 41% limited Wegener's and 10% systemic rheumatoid vasculitis during follow up ranging from 23 to 40 months. to Systemic rheumatoid vasculitis ( Table 8) Systemic vasculitis is a rare but potentially serious complication of rheumatoid arthritis characterized either by a necrotizing arteritis, similar to polyarteritis nodosa, or smaller vessel vasculitis associated with active systemic extra-articular manifestations. Many patients relapse without effective treatment and the four-year mortality in most series is around 33%.48 Cutaneous vasculitis 
Clinical features
Most patients have a long-standing disease of 10 years or more although we have seen five patients where vasculitis either preceded or occurred within three months of the onset of arthritis. Most patients present with cutaneous lesions including nailfold or edge infarcts, leg ulcers or peripheral gangrene (Table 8) , but systemic rheumatoid vasculitis is commonly associated with the entire clinical spectrum of extra-articular features of rheumatoid arthritis. Early studies showed a high frequency of neurological involvement, especially mononeuritis, but our studies suggest that a combination of both significant peripheral neuropathy and mononeuritis occurs in less than 20% of cases.
Pathology
The histological examination of the involved 
Treatment
In the presence of systemic vasculitis aggressive immunosuppressive treatment again appears to be the most useful with uncontrolled studies showing significant benefit with cyclophosphamide compared with conventional antirheumatic therapy'? (Figure 3a-<1 ). Occasionally plasma exchange may be used but its benefit is short-lived and the best results in difficult cases are obtained by combining plasma exchange together with cyclophosphamide and steroids.w It is suggested that the high frequency of systemic rheumatoid vasculitis seen in the 1960s and 1970s was associated with the use of high-dose sreroids.>' We have seen vasculitis flare with a change of steroid dose but now the majority of patients who develop typical rheumatoid vasculitis do so without any steroid treatment. High-dose steroids are immunosuppressive, anti-inflammatory and also anti-emetic and are clinically useful when combined with cyclophosphamide; this combination is significantly better tolerated than cyclophosphamide alone. The potential of longterm continuous oral steroids to produce vascular occlusion associated with endothelial and smooth muscle proliferation 52 ,53 is recognized so we prefer to use intermittent pulsed therapy.
Other treatments reported to benefit rheumatoid vasculitis include low-dose continuous cyclophosphamide, methotrexate and chlorambucil, but the numbers of patients included in these studies are small. 48 ,54 
Churg-Strauss vasculitis
In 1951 Churg and Strauss described the histological findings at autopsy in 13 patients who had a history of asthma, fever and eosinophilia associated with severe systemic upset. The dominant histological finding was a granulomatous vasculitis associated with tissue eosinophilia which was considered the most important diagnostic criterion for the condition named after these authors. 55 Lanham et al. 56 subsequently defined Churg-Strauss vasculitis clinically as a triad of asthma , eosinophilia and systemic vasculitis involving two or more extrapulmonary organs. More recently the American College of Rheumatology reported classification criteria for Churg-Strauss vasculitis ( Table 9 ). These also concentrate on the clinical features including vasculitis and allergy because granulomas, though e~sy to find at necropsy, are not always found at biOpsy leading to previous under-reporting of this condition.
a)
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The treatment of Churg-Strauss vasculitis is controversial. Early studies from tertiary referral centres suggested that steroids alone arc usually adequate to control disease activity.>? We usually have to add cyclophosphamide, particularly in patients with significant renal impairment, and our experience is similar to other series suggesting that pulsed cyclophosaphamide is useful in the acute phase 58 
Other systemic vasculitides
Beh~etts syndrome
In 1937, Behcet first described a chronic relapsing inflammatory disease characterized by recurrent aphthous stomatitis with two or more of aphthous genital ulceration, uveitis , cutaneous nodules or pustules, synovitis and meningoencephalitis.w The frequency of involvement of the various organs in Behcet's disease is outlined in Table 10 .
The frequency of Behcet's syndrome varies c) markedly in different countries, being quite rare in the UK , and its aetiology is unknown. The pathology includes vasculitis, particularly involving large arteries.s! Treatment obviously depends on the severity of organ involvement, and aggressive therapy is usually reserved for patients with vascular disease and ocular disease. Chlorambucil (up to 0.2 mg/kg/day) is particularly effective for severe eye involvement. Methotrexate, azathioprine and cyclophosphamide have also been used with good effect in ocular and neurological Behc;et's.62 Cyclosporin A is preferable to colchid) given within 10 days of onset and is followed by a significant reduction in the incidence of coronary artery involvement. 67 Low-dose aspirin is sometimes used to reduce the risk of thrombosis.
Childhood vasculitis has recently been extensively reviewed by Dillon. 68
Lesion or involvement 1) Apthous stomatitis 2) Genital ulceration 3) Uveitis 4) Synovitis 5) Cutaneous lesions 6) Central nervous system 7) Major vessel occlusions or aneurysms
cine in the treatment of uveitis and mucosal and skin ulceration.63
Kawasaki disease (Table 11) In 1967 Kawasaki described 50 children aged between two months and nine years who devel-. oped an acute illness characterized by swinging fever, mucosal inflammation, skin rash and generalized lymphadenopathy. These features suggested a form of childhood exanthem, but the importance of this disease is that significant numbers of children develop coronary artery disease characterized by aneurysm formation or ectasia (over 20%) and some (2%) die with rupture of coronary artery aneurysms.v'k Vasculitis Involving other organs is also described in some patients. The aetiology of Kawasaki disease is still unknown with some, but not all, authors reporting evidence of retroviral infection.s" IgM ANCA have been described in some patients, and the serum is cytotoxic to activated endothelial cells in vitro suggesting a direct immunological attack on endothelial cells as one possible mechanism for the vascular damage. 2o , 66 Steroids are contra-indicated for the treatment of Kawasaki syndrome as they increase the risk of aneurysm formation. The treatment of choice . is intravenous immunoglobulin, which needs to be predominantly affects persons over the age of 50 years.s?
Giant cell arteritis was first described by Hutchinson?" in 1890; subsequently Horton et al.t! described two further cases in which histological findings were first described. Since then, giant cell arteritis has been much discussed, well recognized and effectively treated. Giant cell arteritis is a common disorder in the USA and Europe, affecting mainly the white population. There are some variations in incidence in Europe. Annual incidence ranges from 6.9 to 18.3 per 100 000 individuals aged 50 years or more 72,73 depending on entry criteria. This wide variation in incidence may reflect environmental factors. Prevalence (based on hospital records) varies from 1.39/1000to 13.5/1000. 74 The aetiology of giant cell arteritis is unknown. An infectious process is suggested'" and is sup- 
r.bl.12 Clinical featuresof giantcell arteritis
ported by the presence of antibodies to intermediate filaments which often occur in patients with viral infections.t« Its occurrence in first degree relatives of patients with this condition, the increased prevalence in Europeans and the occasional familial aggregation suggest a genetic relationship, possibly linked to the immune system, and there is a weak but well-documented association with HLA-DR4 and _B8.77
Clinical features
Giant cell arteritis produces a wide range of clinical symptoms, but most patients have clinical findings referable to involved arteries at some time during the illness ( Table 12 ). The mean age at onset is 69 years with a range of 50-90 years.
Women are affectd twice as often as men. 78 Giant cell arteritis classically presents with temporal headache, visual symptoms with or without symptoms of jaw or tongue claudication. However, it can also present with constitutional symptoms such as anorexia, weight loss, fatigue, malaise and pyrexia of unknown origin. Rarely, patients can present with a sudden onset of blindness in one eye. Inflammation unrelated to the arteries may occur, causing symptoms such as arthritis and pericarditis. Occasionally the arteritis may be the cause of cerebrovascular accidents and multi-infarct dementia. Up to 10% of patients with giant cell arteritis have clinical evidence of large vessel involvement, particularly in the extremities.
There is no laboratory test for the diagnosis of giant cell arteritis. A moderately elevated ESR is characteristic although the condition can occur with a normal ESR in up to 30% of cases.I? CRP may be a more accurate measure of disease progression than ESR, with a rapid fall after treatment and a rise with clinical relapse. so A recent study points out that giant cell arteritis should be considered in the differential diagnosis of elderly patients who present with occipital pain and a normal ESR, 81 The diagnosis of giant cell arteritis may be difficult because the findings and presentations are diverse. It should, however, be considered in all patients over the age of 50 years who have developed transient or sudden visual changes associated with headache, prolonged fever and/or polymyalgia rheumatica. The arteries of the head, neck and extremities should be examined care-fUlly for tenderness, enlargement or alterations in pulses and bruits.
A temporal artery biopsy is recommended in all patients suspected of having this disease. Ã hort segment of the artery is usually sufficient If the artery is obviously abnormal, but in cases Where the artery is apparently normal a 4-6 em temporal artery biopsy is suggested. The specimen should be examined at multiple levels.s-If the first temporal artery is normal the opposite side should be biopsied, as in 15-20% of cases histological evidence of giant cell arteritis may be evident only on the second biopsy. 7 1 ,72 The treatment of giant cell arteritis is with corticosteroids. The aim of treatment is to prevent ischaemic catastrophes, especially blindness. The main controversy today concerns the initial dose and the length of treatment required. The mean duration of treatment varies in different series. 83 In one prospective study84 only 25% of patients with biopsy proven giant cell arteritis were able to stop taking steroid therapy by two years. Anderson 85 estimated the mean duration of treatment to be five years using lifetable analysis. Studies from the US have reported a shorter duration of the disease,86 75% of the patients being able to stop treatment by two years with a median duration oftreatment of 11 months.
. Despite the various recommendations made for the appropriate dose of steroid therapy, the doses used by clinicians are somewhat empirical. We recommend initial treatment with 20 mg prednisolone three times a day for three weeks, fOllowed by 60 mg daily for three weeks, then 40 mg a day for two weeks, 30 mg a day for two Weeks and 20 mg a day for another two weeks, depending on the clinical response. Further reductions of steroid depend on careful clinical assessment, aided by the common laboratory tests
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such as ESR and CRP. Our practice is to attain a daily dose of 15 mg by three months and then reduce by 1 mg increments every month.
Steroid-sparing agents are rarely required but we sometimes use azathioprine (2 mg/kg/day) when the maintenance dose of steroid is 15 mg/day or more.
We aim to withdraw steroids if possible by 18-24 months. Any symptoms of clinical relapse during the period of remission are treated with an immediate increase in the daily dose of prednisolone to 20 mg, particularly in the presence of a significant but inexplicable acute phase response. In our and others' experience, alternate day steroid therapy has met with little success. so Seventy per cent of relapses are usually seen if the dose of prednisolone is reduced to 20 mg within the first two months.
It is important not to withdraw steroid therapy prematurely. In general, patients should be warned to expect to continue treatment for at least 18 months. Monitoring for relapse should continue from six months to one year after the cessation of steroid therapy. Patients should be advised to report immediately if there is a recurrence of previous symptoms or visual disturbance.
Several survival studies of giant cell arteritis have shown the same life expectancy as the general population.s? The risk of death in the untreated disease is not known, although a high mortality has been reported due to associated vascular complications such as myocardial infarction and stroke. 88
Takayasu's arteritis
Takayasu's arteritis is a chronic granulomatous panarteritis affecting large elastic arteries, such as the aorta and its major branches and less commonly the pulmonary arteries.
This condition is rare in the UK but not uncommon in Asia, Mexico and the Far East. Its incidence is 2.6 cases per million per year in the USA and 1.2 cases per million per year in Sweden.
Takayasu's arteritis predominantly affects females (female:male ratio of 8:1) below the age of 40 years (range 15-45 years). As with other vasculitides there are now classification criteria (Table 13 ).89Classification depends on the abnormalities detected in large proximal arteries in subjects under the age of 40. The clinical features of Takayasu's arteritis are shown in Table 14 . The early (inflammatory) stage is characterized by non-specific symptoms of inflammation such as fever (pyrexia of linknown origin), myalgia, arthralgia, weight loss and anaemia with few symptoms of vascular damage. However, visual symptoms can be a presenting feature in 30%, with retinal microaneurysms, venous dilatation and beading, Other organ involvement can occur such as acute myocarditis and crescentic glomerulonephritis.
The early inflammatory phase may evolve into the late ischaemic/pulseless phase over a period of months or years. Sometimes there are distinct phases of inflammation and pulselessness, separated by gaps of apparent normality. The late symptoms are due to ischaemia from narrowed arteries predominantly in the upper limbs. It is important to detect the presence of multiple vascular bruits or absent pulses in the upper extremity. The bruits are usually present over the abdominal aorta and carotids (70%) and less commonly over the subclavian vessels.
The diagnosis of Takayasu's arteritis is usually confirmed by angiography. The classicalfinding is a diffuse narrowing of the artery with occasional poststenotic dilatation. This contrasts with infective arteritis, where narrowing is not a feature and aneurysm formation is common. The treatment of Takayasu's arteritis is usually with corticosteroids alone, the response rate varying between 20 and 100%. We recommend high-dose steroid therapy (up to 60 mg/day) during the inflammatory phase of the disease with gradual reduction of steroid dosage over six to nine months. The role of immunosuppressive therapy is difficult to assess. We have treated two patients with intermittent cyclophosphamide; both responded well, although one relapsed after withdrawal of the drug.
Surgical treatment is beneficial in selected cases, particularly after the inflammatory phase of the disease has been controlled by means of medical treatment. Operative procedures include bypass of stenosed segments of arteries, resection of aneurysms and aortic valve replacement.
The prognosis of Takayasu's arteritis is poorly documented and is usually related to complications such as myocardial infarction, heart failure, cerebrovascular accident and rupture of the aneurysm associated with prolonged disease. A five-year survival of over 90% has been reported in patients on treatment which fell to 56% in the presence of specific complications such as cardiac, . cerebral and renal disease.
Specific drug therapy
Cyclophosphamide
Cyclophosphamide has been used to treat a wide spectrum of vasculitic diseases, including classical and microscopic polyarteritis nodosa, Churg-Strauss vasculitis and systemic rheumatoid vasculitis, with success.P? The major concern with cyclophosphamide treatment is bladder toxicity. Bladder involvement is due to the effect of a urinary metabolite of cyclophosphamide, acrolein, which produces a benign irritating cystitis but occasionally severe haemorrhagic cystitis. .The incidence of bacterial infection in the earlier reports was low, but a recent study on a relatively small number of patients by Bradley et a/. 91 found no obvious correlation between bacterial infection and either the dose of cyclophosphamide or the degree of leucopenia.
The duration of treatment with continuous oral cyclophosphamide is empirical. Fauci et al. recommend continuing treatment for at least one year after remission has been achieved with an option to convert to alternative less aggressive Clinical aspects ofsystemic vasculitis in adults 213 immunosuppressive treatment at that stage (e.g. with azathioprine).
An intermittent pulsed regimen (Table 15 ) was developed in an attempt to reduce cyclophosphamide toxicity based on experience first with systemic rheumatoid vasculitis and because of the proven benefit of pulsed treatment in lupus nephritis. There is now considerable experience with these regimens (oral and intravenous pulses) and we have experience of treating 94 patients with systemic vasculitis (polyarteritis nodosa, Wegener's granulomatosis and systemic rheumatoid vasculitis) and compared intermittent pulsed cyclophosphamide treatment with conventional continuous oral cyclophosphamide. The pulsed regimens were associated with a lower mortality (12% v 23%) and a lower relapse rate (9% v 31%). Pulsed cyclophosphamide is well tolerated in most patients and is particularly effective at inducing initial remission (93%) in Wegener's granulomatosis. The high dose of steroid acts as an anti-emetic as well as immunosuppressive and anti-inflammatory drug. Some patients still suffer nausea which usually responds to metoclopramide or domperidone .
It is important to monitor patients closely, especially between the first and second pulse. Full blood counts are taken at seven, 10 and 14 days. If the lowest white count (usually at 10 days) is below 3 X 109/1, the next dose of cyclophosphamide is reduced; if the white count at 14 days is below 4 x 10 9/1, or is below the 1O-day white count, then treatment is delayed until the bone marrow has recovered. Adjustments are also made according to renal function because cyclophosphamide is excreted by the kidney. If the serum creatinine is more than 200 umol/l the dose of cyclophosphamide is reduced to 10 mg/kg.
Over the last 10 years we have treated over 200 patients with pulsed cyclophosphamide (oral and intravenous) and have never seen haemorrhagic cystitis, so we do not routinely use acetylcysteine (Mesna).
The details of the intermittent oral cyclophosphamide regimen and our own experience with it is shown in Tables 15 and 16. The high dose of prednisolone was chosen to be immunosuppressive and to reduce the expression of activation antigens on endothelial cell surfaces. 92
Corticosteroids
Corticosteroids alone are used to treat small vessel vasculitis (group 2) and giant cell arteritis and Takayasu's arteritis (group 3). Additional cytotoxic therapy is rarely required in these groups though our small experience of Takayasu's arteritis suggests that cyclophosphamide may be required in some cases (two out of six) because of relapses on oral prednisolone. We have also used cyclophosphamide to treat one patient with aortic arch arteritis complicating giant cell arteritis whose disease relapsed on a relatively high dose (30 mg/day) of oral prednisolone.
Steroids alone are still used by some clinicians to treat systemic vasculitis, including polyarteritis nodosa.S' but our own limited experience, and Table15 Cyclophosphamide treatment regimens Oral that of Fauci, suggests that continuous oral prednisolone simply masks 'grumbling arteritis' and frequently relapse occurs when the dose is reduced.
Other drugs
Methotrexate has been used to treat severe systemic rheumatoid vasculitis characterized by cutaneous ulceration.v' Felty's syndrome, systemic lupus erythematosus associated with vasculitis and also polymyositis associated with vasculitis with good effect. 94 The usual dosage used is 10-15 mg per week with resolution of rheumatoid ulcers reported within three to six months. Our own experience is limited to six patients, but intermittent methotrexate had little significant effect on severe systemic rheumatoid vasculitis, no effect on more chronic rheumatoid ulcers, though some benefit to less severe lesions such as nailfold infarcts and episcleritis. Methotrexate hask occasionally been associated with severe pneumonitis (Fig. 4) .
Chlorambucil has been used most frequently to treat Behcet's syndrome, especially if associated with uveitis or meningoencephalitis. There are also reports of some success in a few patients with Wegener's granulomatosisve and systemic lupus erythematosus. 97 Azathioprine is rarely used as a 'first-line' agent for systemic vasculitis, but it is more frequently used in patients who are in remission from more Intensive regimens such as those described with cyclophosphamide, often after three to six months in polyarteritis nodosa, or after a year to 18 Figure 4 Methotrexate pneumonitis developing in a patient with rheumatoid arthritis on methotrexate 10 mg/week after only three months. He responded well to stopping methotrexate and the addition of steroids. although he was severely ill and hypoxic for three to four days.
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months in Wegener's granulomatosis and systemic rheumatoid vasculitis as these latter diseases in our experience are more prone to relapse. Early controlled studies comparing azathioprine with conventional antirheumatic therapy showed no benefit in systemic rheumatoid vasculitis.w Azathioprine is also used to treat other systemic vasculitides and has been shown in controlled studies to benefit Behcet's uveitis.?'
Cyclosporin is also particularly helpful in Behcet's uveitis'w and has also been used to treat Wegener's granulomatosis with benefit.tv! The experience so far is limited to case reports. Our own experience in one patient was that remission was not maintained; a severe relapse involving kidney and skin responded to conventional doses of oral cyclophosphamide.
We have used cyclosporin A to treat four patients with rheumatoid vasculitis. Two patients with eye involvement (episcleritis and scleritis) responded well, as did nailfold infarcts. However, one patient with more severe disease developed peripheral gangrene leading to amputation despite cyclosporin. Histology confirmed the presence of active vasculitis. A wider experience of this particular drug is clearly required before conclusions can be made about its role in systemic vasculitis.
Plasmapheresis was used widely to treat systemic vasculitis and a variety of other 'autoimmune' diseases in the 1970s and 1980s. Significant clinical benefit was described in patients with rheumatoid vasculitisw and polyarteritis nodosa'v! without any additional treatment in some cases. These studies were uncontrolled and we and others noted a significant risk of relapse after treatment was discontinued. More recent studies combine plasmapheresis with conventional immunosuppressive regimens. One large multicentre study from France showed little difference when patients with polyarteritis nodosa and Churg-Strauss vasculitis were treated with a combination of corticosteroids plus plasma exchange, compared with -the combination of corticosteroids, plasma exchange and continuous oral cyclophosphamide. 1 0 2 The addition of the cyclophosphamide was associated with fewer relapses and a better initial remission rate, but this good response to these regimens (compared with previous studies) suggests that the plasma exchange itself may have had a significant effect on outcome, presumably because of its immunosuppressive properties.
Intravenous immunoglobulin
Intravenous immunoglobulin is the treatment of choice for Kawasaki disease, resulting in a significant reduction in the number of coronary aneurysms which are the most serious complications of Kawasaki disease. l o3 Intravenous immunoglobulin has also been used to treat systemic vasculitis, particularly Wegener's granulomatosis, with good effect in uncontrolled studies.P' To date 25 patients with systemic vasculitis have been treated, including 14 with Wegener's granulomatosis, nine with microscopic polyarteritis and two others with 'ANCA positive' vasculitis. Patients were treated with intravenous immunoglobulin after they had either failed to respond to or had severe complications with conventional cytotoxic therapy. Treatment is given by infusing 2 glkg immunoglobulin over three to five days. Twenty-one out of the 23 patients showed improvement in disease activity at six weeks with 10 achieving complete remission and nine partial remission at three months. The clinical improvement is associated with an initial rise in ANCA and sustained rises in the levels of unrelated antibodies and in total IgM in the patients' sera before a fall in ANCA titre to 50% of pretreatment levels by six weeks. It is thought that the immunostimulation by intravenous immunoglobulin is associated with its therapeutic effect accompanied by in vivo regulation of ANCA production, possibly by anti-idiotype antibodies with specificity against a public epitope on ANCA.lOS Dapsone has been used especially to treat unusual forms of cutaneous vasculitis, including erythema elevatum diutinum'w and pyoderma gangrenosumv? as well as bullous skin lesions complicating systemic lupus erythematosus.Ps Dapsone has occasionally been used to treat more systemic vasculitides, including Behcet's syndrome and relapsing polychondritis, and controlled studies have suggested improvement in some patients with polymyalgia/giant cell arteritis. lOB Thalidomide is particularly effective in treating Behcet's oral uiceration. 109 It has also been reported to benefit erythema nodosum leprosum.uv A number of other drugs have been used in small numbers, particularly in Behcet's syndrome, including colchicine with reported successu! and levamisole.tt-There is increasing interest in the use of monoclonal antibodies to treat autoimmune diseases, including rheumatoid arthritis. Campath IH, a genetically engineered 'humanized' form of rat antibody which belongs to the CDw52 cluster (capable of depleting human lymphocytes), has been used to treat one patient with intractable systemic vasculitis and was associated with marked clinical improvement. A similar antibody to the human CD4 molecule on T helper cells has also been reported to be of benefit. It has to be noted that there is also one report of vasculitis affecting the temporal arteries in a patient treated with monoclonal antibodies for graft rejection in which mouse immunoglobulin was found to be deposited within the walls of the affected artery, suggesting that, as in serum sickness, foreign monoclonal antibodies may also be responsible for vasculitis.
